Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Melbourne based therapeutic antibody development group, Patrys Limited, has updated the market on a range of new activities being pursued. 

Previously stated in October 2018, an international service provider for the development of PAT-DX1 had been selected. This partnership will advance the clinic as a stable cell line, which is a critical component for the development of the pathway for therapeutic antibodies. 

PAT-DSX1 could potentially be used for the treatment of a broad range of cancers with impaired DNA damage repair, most likely for glioblastoma, cancer affecting the brain or spine, and triple negative breast cancer. 

Patrys Limited hopes to announce the results from two studies conducted at the beginning of the year. The first experiment is still ongoing and the results for the second will not be released until the first experiment is completed. 

Patrys Limited has received several grants from various Australian Government departments resulting around $35,000. These funds are to be used for the upcoming formulation around PAT-DX1 and other antibodies. 

Please find announcement attached: https://hotcopper.com.au/threads/ann-market-update.4691969/

PAB by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Executive Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) shuffles board

Rhythm Biosciences (RHY) has restructured its board and management team, effective immediately.

" Epsilon Healthcare (ASX:EPN) extends agreement with The Valens Company

Epsilon Healthcare (EPN) has extended its agreement with The Valens Company to January 31, 2022.
Starpharma (ASX:SPL)

" Starpharma’s (ASX:SPL) nasal spray registered for sale in Vietnam

Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.  
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.